Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans.
The company's lead therapeutic, ADI-PEG 20, is in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris is also investigating ADI-PEG 20 as a treatment for other arginine-dependent cancers, such as metastatic melanoma, prostate cancer, leukemia, lymphoma, sarcoma and pancreatic cancer.
Polaris is researching and developing other biotherapeutic agents and has a small molecule drug program that utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.